In the realm of medical innovation, a groundbreaking technology is reshaping the landscape of drug discovery and toxicology research – Organs-On-Chips Market. Anticipated to grow at an impressive CAGR of around 32% over the forecast period (2021-2027), Organs-On-Chips represent a paradigm shift in the way pharmaceuticals are developed and tested. These microfluidic cell culture devices replicate the physiological conditions of human organs, offering a level of precision and complexity unattainable with traditional 2D and 3D culture systems.
Access sample report (including graphs, charts, and figures): https://univdatos.com/report/organs-on-chips-market/get-a-free-sample-form.php?product_id=18572
The Power of Organs-On-Chips
Organs-On-Chips, equipped with continuously perfused chambers, emulate vital organs like the lung, heart, liver, and intestine, providing a microenvironment for blood and airflow. The technology's applications are diverse, including patient stratification, disease modeling, and phenotypic screening. One of its key drivers is the urgent need for alternatives to animal testing, reflecting the growing ethical concerns in research. Additionally, Organs-On-Chips enable early detection of drug toxicity, a crucial aspect in pharmaceutical development.
The Lung-On-Chip Revolution
Among various organ types, the lung segment dominates the Organs-On-Chips market. Lung-On-Chip technology, a three-dimensional model of a living human lung, accurately predicts the absorption of airborne nanoparticles and simulates inflammatory responses. This innovation is invaluable in testing environmental toxins, therapeutic absorption, and the safety and efficacy of new drugs. With pulmonary diseases posing significant global health challenges, this technology has emerged as a vital tool in the development of treatments for conditions like tuberculosis.
Transforming Drug Discovery
In the realm of applications, drug discovery takes the lead. Organs-On-Chips offer pharmaceutical and biotechnology companies a cost-effective, miniaturized, and precise platform for drug testing. This technology creates a microenvironment mirroring human physiology, reducing drug failure rates by replacing trial and error with a reliable and efficient process. Amidst increasing competition and decreasing average peak sales, the demand for Organs-On-Chips devices has soared, providing invaluable assistance in the drug discovery process.
Click here to view the Report Description & TOC https://univdatos.com/report/organs-on-chips-market/
North America Leads the Way
Geographically, North America spearheads the Organs-On-Chips market. The region's dominance can be attributed to the availability of diverse services provided by major players, offering customized designs for organ arrangements and conducting toxicological testing of chemicals on various types of organ cells. Leading companies like MIMETAS BV, SynVivo Inc., and Emulate Inc. are driving innovation, pushing the boundaries of what's possible in drug discovery.
In conclusion, Organs-On-Chips represent a transformative leap in pharmaceutical research, offering unprecedented precision and efficiency. With ongoing advancements and a relentless pursuit of medical excellence, the Organs-On-Chips market is set to revolutionize drug discovery, ushering in a new era of innovation and life-saving treatments.
Related Report
Lung Cancer Therapeutics Market
Nasogastric Tube Holders Market
Contact Us:
UnivDatos Market Insights
Email - sales@univdatos.com, contact@univdatos.com
Contact Number - 0120 455 9411
Website - https://univdatos.com/
The report "Organs-on-chips Market by Type (Liver, Kidney, Lung, Heart, Intestines, Gut), Offering (Product, Service), Application (Toxicity testing, Physiological model), End User (Academic, Research institute, Pharma companies) - Global Forecast to 2022", The organs-on-chips market is expected to reach USD 45.6 million by 2022 from USD 9.6 million in 2017, at a CAGR of 36.6%.The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291 The liver-on-a-chip segment is expected to dominate the market in 2017Based on type, the organs-on-chips market is segmented into liver, lung, heart, kidney, and other organs-on-chips.
The large share of this segment can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to the in vivo environment.The drug discovery segment is expected to register the highest CAGR during the forecast period.Based on application, the organs-on-chips market is segmented into physiological model development, drug discovery, and toxicology research.
The increasing focus on drug discovery, rising need for more predictive in vitro tools for drug development among pharmaceutical companies, and growing preference for alternatives to conventional cell culture and animal models are some of the factors that are driving the growth of the drug discovery segment.North America to dominate the organs-on-chips market in 2017.In 2017, North America is expected to dominate the market followed by Europe.
The large share of this geographical segment is attributed to factors such as availability of new and advanced organs-on-chips in the market, and favorable government initiatives in terms of funding and programs for basic drug development and research, and the presence of key pharmaceutical companies.
These are regions where the majority of drug development activity is concentrated.Read more: - https://www.marketsandmarkets.com/PressReleases/organs-on-chips.aspThe organs-on-chips market is emerging and high growth potential market with the presence of several small players and startups firms.
Some of the players in the organs-on-chips market include Emulate (US), CN Bio (UK), TissUse (Germany), Mimetas (Netherlands), InSphero (Switzerland), Ascendance Bio (US), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
A new research report titled global Organs-on-Chips Market report published by Reports and Data provides a brief overview of the industry and gives an estimation of growth and revenue for the forecast period of 2021-2028.
The report further analyzes market segments, size, trends, growth drivers, restraining factors, opportunities and challenges, cost overview, SWOT analysis, and Porter’s Five Forces Analysis.
The report all includes industrial chain analysis, revenue growth, sales estimation, value chain analysis, capacity, regional market examination, and market forecast up to 2028.
The report offers insightful information that will assist in gaining a market position and maximize on lucrative growth opportunities.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4034The report provides a panoramic view of the market and insights that will help formulate better business decisions.
In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions.
The report also discusses in detail about the key factors influencing the market growth.Key companies operating in the market include:Emulate (U.S.), Mimetas (Netherlands), InSphero (Switzerland), CN Bio (UK), AxoSim (U.S.), Ascendance Bio (U.S.), TissUse (Germany), HUREL (HUREL) (U.S.), Kirkstall (UK), SynVivo (U.S.), and Nortis (U.S.).
